Genprex (STU:2DE1) E10: €-4,471,792.91 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2DE1 Genprex Inc STU:2DE1
35 GF Score
Price €7,704.40
! 1 Warning Sign
View Full Analysis

What is Genprex E10?

Genprex STU:2DE1 35 E10 is €-4,471,792.91 as of Mar. 2026. GuruFocus rates STU:2DE1 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genprex's adjusted earnings per share data for the three months ended in Mar. 2026 was €-12.179. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-4,471,792.91 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-23), Genprex's current stock price is €7704.40. Genprex's E10 for the quarter that ended in Mar. 2026 was €-4,471,792.91. Genprex's Shiller PE Ratio of today is .


Genprex  (STU:2DE1) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Genprex E10 Related Terms


Genprex E10 Historical Data

* Premium members only.

The historical data trend for Genprex's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genprex E10 Chart

Genprex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -4,568,329.10

Genprex Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -970,192.10 -4,568,329.10 -4,471,792.91

STU:2DE1 vs MLEC, LIMN, ADIL: E10 Comparison

For the Biotechnology subindustry, Genprex's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genprex's Shiller PE Ratio falls into.


STU:2DE1
35GF Score
Genprex Inc STU:2DE1
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genprex E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genprex's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-12.179/330.2130*330.2130
=-12.179

Current CPI (Mar. 2026) = 330.2130.

Genprex Quarterly Data

per share eps CPI Adj_EPS
201606 -6,283.403 241.018 -8,608.740
201609 -2,166.855 241.428 -2,963.715
201612 -3,199.715 241.432 -4,376.336
201703 -2,373.204 243.801 -3,214.354
201706 -3,551.506 244.955 -4,787.628
201709 -2,026.916 246.819 -2,711.760
201712 -1,902.911 246.524 -2,548.904
201803 -2,107.996 249.554 -2,789.327
201806 -16,471.106 251.989 -21,584.170
201809 -5,477.999 252.439 -7,165.717
201812 -8,716.433 251.233 -11,456.614
201903 -5,412.404 254.202 -7,030.811
201906 -9,109.436 256.143 -11,743.652
201909 -5,992.074 256.759 -7,706.296
201912 -4,994.215 256.974 -6,417.594
202003 -6,752.586 258.115 -8,638.753
202006 -4,428.146 257.797 -5,672.026
202009 -2,629.382 260.280 -3,335.854
202012 -4,389.861 260.474 -5,565.197
202103 -5,174.400 264.877 -6,450.746
202106 -2,921.600 271.696 -3,550.845
202109 -2,618.000 274.310 -3,151.535
202112 -5,451.600 278.802 -6,456.873
202203 -4,394.720 287.504 -5,047.560
202206 -4,994.880 296.311 -5,566.362
202209 -5,777.200 296.808 -6,427.409
202212 -5,607.360 296.797 -6,238.686
202303 -7,643.856 301.836 -8,362.490
202306 -6,233.942 305.109 -6,746.863
202309 -5,524.552 307.789 -5,927.044
202312 -3,822.973 306.746 -4,115.442
202403 -3,906.320 312.332 -4,129.957
202406 -3,065.700 314.175 -3,222.198
202409 -1,222.026 315.301 -1,279.821
202412 -418.879 315.605 -438.267
202503 -264.143 319.799 -272.745
202506 -162.129 322.561 -165.975
202509 -93.720 324.800 -95.282
202512 -21.635 324.054 -22.046
202603 -12.179 330.213 -12.179

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-4,471,792.91 mean?
Genprex (STU:2DE1) has a E10 of €-4,471,792.91 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Genprex and its competitors.
Is Genprex's E10 too high?
Genprex's current E10 is €-4,471,792.91. Overall, Genprex has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Genprex's E10 compare to MLEC and LIMN?
Genprex's E10 of €-4,471,792.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Genprex and its competitors. Genprex's current E10 is €-4,471,792.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genprex stock overvalued right now?
Genprex (STU:2DE1) has a current E10 of €-4,471,792.91. The current E10 is €-4,471,792.91. Genprex's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Genprex (STU:2DE1), the current E10 is €-4,471,792.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genprex Business Description

Other Exchanges GNPX:USA0A8I:UK
Address 3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
35GF Score

Get the complete analysis for STU:2DE1

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7,704.40
Price